Scpharmaceuticals (SCPH) Shares Down 30.1%

Scpharmaceuticals Inc (NASDAQ:SCPH) shares were down 30.1% during trading on Thursday . The company traded as low as $8.91 and last traded at $9.94. Approximately 991,686 shares traded hands during trading, an increase of 1,035% from the average daily volume of 87,384 shares. The stock had previously closed at $14.22.

A number of research analysts have recently commented on SCPH shares. Jefferies Group reaffirmed a “buy” rating and set a $26.00 target price on shares of Scpharmaceuticals in a research note on Wednesday, March 21st. Zacks Investment Research cut Scpharmaceuticals from a “hold” rating to a “sell” rating in a research note on Friday, May 11th. Finally, ValuEngine raised Scpharmaceuticals from a “sell” rating to a “hold” rating in a research note on Wednesday, May 2nd. Two analysts have rated the stock with a hold rating and three have given a buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus target price of $23.33.

The company has a market cap of $257.00 million and a P/E ratio of -1.24. The company has a quick ratio of 19.23, a current ratio of 19.23 and a debt-to-equity ratio of 0.10.

Scpharmaceuticals (NASDAQ:SCPH) last released its earnings results on Monday, May 7th. The company reported ($0.47) EPS for the quarter, beating analysts’ consensus estimates of ($0.51) by $0.04. equities analysts predict that Scpharmaceuticals Inc will post -2.91 earnings per share for the current fiscal year.

Hedge funds and other institutional investors have recently made changes to their positions in the stock. California State Teachers Retirement System purchased a new stake in shares of Scpharmaceuticals in the first quarter valued at approximately $139,000. Schwab Charles Investment Management Inc. purchased a new stake in shares of Scpharmaceuticals in the first quarter valued at approximately $167,000. Monashee Investment Management LLC purchased a new stake in shares of Scpharmaceuticals in the fourth quarter valued at approximately $230,000. Bank of New York Mellon Corp purchased a new stake in shares of Scpharmaceuticals in the fourth quarter valued at approximately $414,000. Finally, Millennium Management LLC purchased a new stake in shares of Scpharmaceuticals in the fourth quarter valued at approximately $462,000. Hedge funds and other institutional investors own 44.86% of the company’s stock.

Scpharmaceuticals Company Profile

scPharmaceuticals Inc, a clinical-stage pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. The company's lead product candidate is Furoscix, a drug-device combination product that is under development for treatment of worsening or decompensated heart failure outside of the inpatient setting.

Receive News & Ratings for Scpharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Scpharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply